Vaccines, oncology, and rare disease programs each carry distinct cost structures, attrition profiles, and funding dynamics. Understanding the differences serves […]

Drug development is expensive, slow, and brutally competitive. A Phase 3 study failure costs hundreds of millions of dollars. A

When developing novel life science technologies, drugs, biologics, and gene or cell therapies, how often do early-stage teams conduct a

*A summary of Pathway Capital’s whitepaper on regulatory strategy in early-stage life science investment There is a gap in how